Compare Onto Innovation (ONTO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Onto Innovation vs Travere Therapeutics Inc. Common Stock — how do they compare? Onto Innovation trades at $234.65 (market cap $12.93B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Onto Innovation is far larger — about 2.6× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Onto Innovation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Onto Innovation for 7 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ONTO | TVTX | |
|---|---|---|
Market Cap | $12.93B | $4.88B |
Volume | 1,098,259 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $378.45 | $67.52 |
52-Week Low | $124.09 | $26.79 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $12.52B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONTO trades at $263.55, down 3.72% with bearish technical signals but strong analyst support. The stock shows mixed earnings performance with a Q2 2026 beat but misses in prior quarters. Revenue grew to $1.01B in 2025 with 11.84% net margin, though valuation remains elevated at P/E 98.71. Recent news highlights a $1.1B backlog and strategic partnerships in semiconductor manufacturing.
Outlook remains positive with 100% analyst buy ratings and $387 consensus target suggesting 47% upside. Key risks include high valuation multiples and semiconductor cycle volatility. Growth catalysts include AI-driven demand and Dragonfly G5 product momentum, though execution on backlog conversion is critical.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Onto Innovation
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
